Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT
| Autor: | Thomas C. Shea, Amber N Essenmacher, Paul Brown, Andrew Sharf, William A. Wood, Kamakshi V. Rao, Jonathan S. Serody, James M. Coghill, Robert Irons, Paul M. Armistead, Julia Whitley, Stefanie Sarantopoulos, Ravi K. Goyal, D. A. Gabriel |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Transplantation medicine.medical_specialty business.industry Plerixafor medicine.medical_treatment Hematology Hematopoietic stem cell transplantation medicine.disease Surgery Granulocyte colony-stimulating factor Lymphoma Regimen Internal medicine medicine Autologous transplantation business Etoposide Hematopoietic Stem Cell Mobilization medicine.drug |
| Zdroj: | Bone Marrow Transplantation. 48:771-776 |
| ISSN: | 1476-5365 0268-3369 |
| Popis: | The effectiveness of stem cell mobilization with G-CSF in lymphoma patients is suboptimal. We reviewed our institutional experience using chemomobilization with etoposide (VP-16; 375 mg/m2 on days +1 and +2) and G-CSF (5 μg/kg twice daily from day +3 through the final day of collection) in 159 patients with lymphoma. This approach resulted in successful mobilization (>2 × 106 CD34+ cells collected) in 94% of patients (83% within 4 apheresis sessions). Fifty-seven percent of patients yielded at least 5 × 106 cells in ⩽2 days and were defined as good mobilizers. The regimen was safe with a low rate of rehospitalization. Average costs were $14 923 for good mobilizers and $27 044 for poor mobilizers (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|